Imrab 3 Tf - 1905.23

Verify with FDA CVM →

259 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
259
Total Reports
22
Deaths Reported
850.0%
Death Rate

Active Ingredients

Imrab 3 Tf - 1905.23

Administration Routes

SubcutaneousUnknownIntramuscular

Species Affected

Dog 251
Cat 8

Most Affected Breeds

Retriever - Labrador 20
Crossbred Canine/dog 19
Chihuahua 17
Retriever - Golden 16
Terrier - Yorkshire 11
Shih Tzu 11
Shepherd Dog - German 10
Boxer (German Boxer) 9
Terrier (unspecified) 9
Dachshund (unspecified) 8

Most Reported Reactions

Vomiting 90
Lethargy (see also Central nervous system depression in 'Neurological') 60
Diarrhoea 57
Other abnormal test result NOS 42
Anorexia 26
Injection site lump 17
Pruritus 17
Not eating 17
Death 13
Seizure NOS 13
Behavioural disorder NOS 12
Injection site swelling 12

Outcome Breakdown

Outcome Unknown
130 (49.8%)
Recovered/Normal
90 (34.5%)
Ongoing
18 (6.9%)
Died
13 (5.0%)
Euthanized
9 (3.4%)
Recovered with Sequela
1 (0.4%)

Data Summary

Metric Value
Total adverse event reports 259
Reports involving death 22
Case-fatality rate (reported events) 850.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imrab 3 Tf - 1905.23 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 259 adverse event reports referencing Imrab 3 Tf - 1905.23, including 22 reports in which the animal died — a 850.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Imrab 3 Tf - 1905.23. Reported administration routes include Subcutaneous, Unknown, Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imrab 3 Tf - 1905.23 reports are Dog (251 reports), Cat (8 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (20), Crossbred Canine/dog (19), Chihuahua (17) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imrab 3 Tf - 1905.23 are Vomiting (90), Lethargy (see also Central nervous system depression in 'Neurological') (60), Diarrhoea (57), Other abnormal test result NOS (42). Of the 261 reports with a coded outcome, Outcome Unknown is the leading category at 49.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imrab 3 Tf - 1905.23.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial